phase 1 trial

Encouraging results were seen in an early-stage trial of ISIS-SMNRx, a drug designed to increase levels of a deficient protein in spinal muscular atrophy

posted on March 21, 2013 - 11:31am
An experimental drug designed to treat the underlying molecular defect in spinal muscular atrophy (SMA) has shown encouraging results in a phase 1 trial.

New content is being added every day. Please check back again.